SuperworthMedtronic plc MDT
Medical - Devices, Healthcare
$85.51
−1.81%
- Market cap
- $109.4B
- PE
- 21.1×
- 10y median 28.4×
- Forward PE
- Price to sales
- 2.9×
- EV/EBIT
- 18.9×
- Revenue, 12 months
- $37.5B
- +10% on a year ago
- Net margin
- 13.9%
- Free cash flow yield
- 5.6%
Medtronic trades at 21.1× trailing earnings, cheaper than 99% of the last ten years. Revenue was $37.5B over the last twelve months, up 10% on a year earlier with a 14% net margin.
Charts
Financials
| Income statement | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $8B | $8.1B | $8.6B | $7.9B | $8.4B+5% | $8.3B+3% | $8.9B+4% | $8.6B+8% | $9B+7% | $9B+9% | $9.8B+10% | $9.8B+14% | |
| Cost of revenue | $2.8B | $2.8B | $3B | $2.8B | $2.9B+7% | $2.8B−0% | $3.1B+3% | $3B+9% | $3.1B+4% | $3.3B+17% | $3.4B+8% | $3.4B+14% |
| Gross profit | $5.2B | $5.3B | $5.5B | $5.2B | $5.5B+5% | $5.5B+4% | $5.8B+4% | $5.6B+8% | $5.9B+8% | $5.8B+4% | $6.4B+11% | $6.3B+14% |
| R&D | $698M | $695M | $675M | $676M | $697M−0% | $675M−3% | $684M+1% | $726M+7% | $754M+8% | $722M+7% | $671M−2% | $771M+6% |
| SG&A | $2.7B | $2.7B | $2.8B | $2.7B | $2.8B+3% | $2.7B+2% | $2.7B−2% | $2.8B+6% | $3B+8% | $3B+9% | $3.1B+12% | $3.2B+14% |
| $1.3B | $1.5B | $1.1B | $1.3B | $1.6B+19% | $1.6B+11% | $1.4B+36% | $1.4B+13% | $1.7B+6% | $1.5B−11% | $1.9B+30% | $1.8B+22% | |
| Interest expense | $180M | $188M | $202M | $167M | $209M+16% | $179M−5% | $174M−14% | $176M+5% | $181M−13% | $181M+1% | $177M+2% | $186M+6% |
| Pre-tax income | $1.3B | $1.5B | $855M | $1.3B | $1.6B+19% | $1.5B+5% | $1.3B+48% | $1.3B+3% | $1.6B+2% | $1.4B−9% | $1.8B+45% | $1.8B+36% |
| $402M | $135M | $197M | $220M | $281M−30% | $237M+76% | $199M+1% | $255M+16% | $215M−24% | $254M+7% | $575M+189% | $289M+13% | |
| Net income | $909M | $1.3B | $654M | $1B | $1.3B+40% | $1.3B−2% | $1.1B+62% | $1B−0% | $1.4B+8% | $1.1B−12% | $1.2B+18% | $1.5B+41% |
| $0.68 | $0.99 | $0.49 | $0.80 | $0.99+46% | $1.01+2% | $0.82+67% | $0.81+1% | $1.07+8% | $0.89−12% | $0.96+17% | $1.14+41% | |
| 1.3B | 1.3B | 1.3B | 1.3B | 1.3B−3% | 1.3B−3% | 1.3B−3% | 1.3B−1% | 1.3B+0% | 1.3B+0% | 1.3B+0% | 1.3B−0% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Devices within ten times Medtronic's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MDTMedtronic plc | $109.4B | 21.1× | 28.4× | 2.9× | +10% | 13.9% | |
| SYKStryker Corporation | $105.6B | 28.5× | 41.2× | 4.1× | +8% | 14.4% | |
| ABTAbbott Laboratories | $170.8B | 31.8× | 36.2× | 3.7× | +8% | 11.6% | |
| BSXBoston Scientific Corporation | $60.3B | 16.8× | 66.3× | 2.9× | +14% | 17.5% | |
| EWEdwards Lifesciences Corporation | $49.4B | 49.3× | 40.5× | 7.6× | +15% | 15.4% | |
| DXCMDexCom, Inc. | $31.8B | 33.3× | 142× | 6.4× | +16% | 20.1% | |
| GEHCGE HealthCare Technologies Inc. | $29.2B | 18.7× | 19.9× | 1.4× | +7% | 9.3% | |
| Peer median | $54.9B | 30.2× | 40.8× | 3.9× | +11% | 14.9% |
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .